Selected article for: "infection control and proper infection control"

Author: Ahlawat, Shruti; Asha; Sharma, Krishna Kant
Title: Immunological co-ordination between gut and lungs in SARS-CoV-2 infection
  • Cord-id: k96sb9i2
  • Document date: 2020_7_24
  • ID: k96sb9i2
    Snippet: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into a major pandemic called coronavirus disease 2019 (COVID-19) that has created unprecedented global health emergencies and emerged as a serious threat due to its strong ability for human-to-human transmission. The reports indicate the ability of SARS-CoV-2 to affect almost any organ due to the presence of a receptor known as angiotensin converting enzyme 2 (ACE2) across the body. ACE2 receptor is majorly expressed in bru
    Document: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into a major pandemic called coronavirus disease 2019 (COVID-19) that has created unprecedented global health emergencies and emerged as a serious threat due to its strong ability for human-to-human transmission. The reports indicate the ability of SARS-CoV-2 to affect almost any organ due to the presence of a receptor known as angiotensin converting enzyme 2 (ACE2) across the body. ACE2 receptor is majorly expressed in brush border of gut enterocytes along with the ciliated cells and alveolar epithelial type II cells in lungs. The amino acid transport function of ACE2 has been linked to gut microbial ecology in gastrointestinal (GI) tract, thereby suggesting that COVID-19 may, to some level, be linked to the enteric microbiota. The significant number of COVID-19 patients shows extra-pulmonary symptoms in the GI tract. Many subsequent studies revealed viral RNA of SARS-CoV-2 in fecal samples of COVID-19 patients. This presents a new challenge in the diagnosis and control of COVID-19 infection with a caution for proper sanitation and hygiene. Here, we aim to discuss the immunological co-ordination between gut and lungs that facilitates SARS-CoV-2 to infect and multiply in the inflammatory bowel disease (IBD) and non-IBD patients.

    Search related documents:
    Co phrase search for related documents
    • accessory protein and acute respiratory distress: 1, 2, 3
    • accessory protein and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • accessory protein and lung epithelial cell: 1, 2
    • acquire immunity and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and long term outcome: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and low airway: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and low mortality rate: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and low respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute phase and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
    • acute phase and additional insight: 1
    • acute phase and long term outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute phase and low respiratory: 1
    • acute phase response and adaptive immunity: 1
    • acute phase response and long term outcome: 1
    • acute respiratory distress and long term outcome: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory distress and low airway: 1, 2, 3, 4, 5, 6
    • acute respiratory distress and low mortality rate: 1, 2, 3, 4, 5
    • acute respiratory distress and low respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25